Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 7Ovarian Neoplasms 6Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Urogenital Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Rectal Neoplasms 2Multiple Myeloma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

Specimen Handling 43pembrolizumab 42Biopsy 36Magnetic Resonance Spectroscopy 34Paclitaxel 21Carboplatin 21Gemcitabine 20Nivolumab 19Irinotecan 17Radiosurgery 15Cisplatin 13Taxes 11Pemetrexed 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Fulvestrant 8X-Rays 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × aldesleukin × 90 days × Clear all
NCT02133196 2026-06-05

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
85 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
27 enrolled 10 charts
Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡